



FRIDAY 14 AUGUST 2026	
0700-1900	Registration Open (Level 2, Foyer 1)
0800-1900	Industry Exhibition Open (Melbourne Room 1)
0800-1000	Conference Opening, Multidisciplinary Plenary and Patrick C Walsh Lecture
Room	Melbourne Room 2
0800-0805	Conference Opening Dr Phil Dundee, <i>Convenor</i>
0805-0825	Balancing early detection, overdiagnosis and efficient use of healthcare resources Associate Professor Anna Lantz
0825-0845	Re-defining clinically significant prostate cancer - challenging the dogma Associate Professor Kara Watts
0845-0905	Active surveillance in 2026: Imaging lead patient selection and follow-up Associate Professor Giorgio Gandaglia
0905-0925	What do our patients want us to talk about? Issues of intimacy and sexuality in prostate cancer Dr Amanda Hordern
0925-0945	Patrick C Walsh Lecture Radioligand therapy 2026: Initial developments and future concepts Professor Oliver Sartor
0945-1000	Q&A discussion
1000-1030	Morning Tea & Industry Exhibition (Melbourne Room 1)

1030-1230	Session 1A: Clinical Urology	1030-1230	Session 1B: Nursing & Allied Health
Theme	Screening, biomarkers and population health & Rapid Fire Presentations	Theme	Precision medicine: The changing landscape of prostate cancer detection, diagnosis & focal therapy
Room	Melbourne Room 2	Room	Meeting Rooms 203 & 204
1030-1050	Implementing PSA screening programs – real-world lessons from a preparatory program Associate Professor Anna Lantz	1030-1050	Beyond PSA – emerging biomarkers for prostate cancer in Australia Associate Professor Matthew Roberts
1050-1110	PSA screening in modern practice – who, when, how? Associate Professor Kara Watts	1050-1110	From Guidelines to Practice: Applying the 2026 Australian early detection of prostate cancer recommendations Associate Professor David Smith
1110-1130	Australian perspective – 2026 Guidelines on Risk adapted testing, MRI and Active surveillance Professor Peter Heathcote	1110-1130	Introducing a Nurse-Led TP biopsy service Ms Debbie Victor
1130-1150	Biomarkers in screening - Stockholm3 and beyond Associate Professor Anna Lantz	1130-1150	The future in a surveillance society Professor Niall Corcoran
1150-1210	Imaging as a biomarker - bypassing biopsy Associate Professor Matthew Roberts	1150-1210	The emerging role of focal therapy in prostate cancer. patient selection, oncological outcomes, and functional results Associate Professor John Yaxley
1210-1215	Rapid Fire Presentation Prostate cancer risk after male breast cancer: a population based study and implications for targeted surveillance Mr Basil Razi	1210-1230	Salvage management after focal therapy failure Professor Jonathon Coleman
1215-1220	Rapid Fire Presentation Performance of MiCheck®Prostate MRI versus PHI in patients with a prior biopsy Mr Douglas Campbell		
1220-1225	Rapid Fire Presentation Validation of the ePI-FAB score to predict residual disease following cooled focal laser ablation with ProFocalTM in prostate cancer Dr Ymer Bushati		
1225-1230	Rapid Fire Presentation Prostate cancer prevention beyond pharmacology: An update on nutraceuticals and lifestyle interventions Miss Jacinta Bonaddio		
1230-1330	Lunch, Industry Exhibition & Poster Viewing (Melbourne Room 1)		

1330-1530	Session 2A: Clinical Urology	1330-1530	Session 2B: Nursing & Allied Health
Theme	Imaging and risk stratification	Theme	Innovations in treatment of localised prostate cancer
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
1330-1350	MRI dilemmas: PIRADS 3 and racial disparities Presenter to be confirmed	1330-1350	Innovations in surgery for prostate cancer Associate Professor Alvin Goh
1350-1410	GenI-AIRSPACE Professor Niall Corcoran	1350-1410	Standardized collection of complications after radical prostatectomy - "If you can't measure it, you can't improve it" Associate Professor Giorgio Gandaglia
1410-1430	Upgrading on AS: biology vs sampling error Associate Professor Kara Watts	1410-1430	Beaming on in 2026 - Shining the light on Radiotherapy Dr Ee Siang Choong
1430-1440	Low diagnostic yield of PSMA PET/CT in ISUP grade group 2/3 prostate cancer: A prospective multicentre analysis Miss Jacinta Bonaddio	1430-1450	Optimizing quality of life post prostate SBRT Professor Sean Collins
1440-1455	PSMA PET: staging, recurrence, and limitations Professor Rod Hicks	1450-1510	Navigating uncertainty: misinformation, decision-making, and treatment regret in prostate cancer Dr Maria Ftanou
1455-1505	Near-Universal PSA response to stereotactic radiotherapy provides biological support for long axial field of view PSMA-PET/CT in identifying clinically relevant disease in biochemical recurrence of prostate cancer Dr Paul Conway	1510-1520	Robocare Patient-Directed Online Package (RoboPOP): A transitional modular approach to digital patient education pre-robot-assisted radical prostatectomy Tiphany Catalan
1505-1525	Debate Modern biopsy techniques: Target biopsy only Associate Professor Jeremy Grummet Modern biopsy techniques: Systematic plus target biopsy Additional participants to be announced	1520-1530	Transperineal fiducial marker implantation under local anaesthetic in an outpatient setting: nursing considerations Ms Karen Kennedy
1530-1600	Afternoon Tea & Industry Exhibition (Melbourne Room 1)		

1600-1745	Session 3A: Clinical Urology	1600-1745	Session 3B: Nursing & Allied Health
Theme	Robotic Prostatectomy in the Multi-Platform Era: Current Systems, Emerging Technologies and Clinical Impact	Theme	Managing the whole person: Quality of Life in Prostate Cancer
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
1600-1620	Improving robotic surgical performance through proficiency-based simulation training Associate Professor Alvin Goh	1600-1615	Eating well with prostate cancer: evidence, myths, and the supplement question Dr Brenton Baguley
1620-1640	Standardized collection of complications after radical prostatectomy - "If you can't measure it, you can't improve it" Associate Professor Giorgio Gandaglia	1615-1630	Beyond the Expected: Pelvic floor physio case studies in prostate cancer care Ms Lauren Clarke
1640-1700	Can fluorescence enhanced intraoperative imaging improve radical prostatectomy? Associate Professor Alvin Goh	1630-1645	From evidence to action: having the exercise conversation with prostate cancer patients Professor Prue Cormie
1700-1720	Where do robotic platforms fit in the future of prostate cancer surgery? Professor Jonathon Coleman	1645-1715	Sex talk in clinical practice: Why is it so hard? Dr Amanda Hordern
1720-1730	Innovative application of fat sling technique in robot-assisted laparoscopic radical prostatectomy to improve postoperative urinary incontinence Dr Lijun Mao	1715-1730	Penis Potions: understanding intracavernosal formulations Ms Francesca Rogers
1730-1740	Update on PCOR - where has the data gone and how do we measure national outcomes? Associate Professor Marlon Perera	1730-1745	Q&A discussion
1740-1900	Robotic Platforms Hands On Demonstrations in the Industry Exhibition		
1745-1900	Industry Welcome Reception (Melbourne Room 1)		
1900-2130	Satellite Dinner Meetings		

SATURDAY 15 AUGUST 2026

0645-1730	Registration Open (Level 2, Foyer 1)
0715-0830	Breakfast Session proudly supported by Astellas
Title	Navigating the new standard of systemic treatments in HSPC
Room	Meeting Room 203 & 204
Chairs	Associate Professor Matt Roberts
Speakers	Program released soon
0800-1615	Industry Exhibition Open (Melbourne Room 1)
0845-1045	Multidisciplinary Plenary
Room	Melbourne Room 2
0845-0905	The role of radical prostatectomy in locally advanced and oligometastatic disease Associate Professor Alvin Goh
0905-0925	SBRT in oligometastatic prostate cancer: does ablation change outcomes or just select better biology? Professor Sean Collins
0925-0945	mCRPC: where do PARP inhibitors and combinations fit? Professor Oliver Sartor
0945-1005	Social media and cancer awareness Associate Professor Kara Watts
1005-1025	PIONEER & Big Data: the future of prostate cancer research Associate Professor Giorgio Gandaglia
1025-1045	Q&A discussion
1045-1115	Morning Tea & Industry Exhibition (Melbourne Room 1)

1115-1245	Session 4A: Clinical Urology	1115-1245	Session 4B: Nursing & Allied Health
Theme	Oligometastatic and locally advanced disease & Abstract Presentations	Theme	Prostate cancer in the outback & Abstract Presentations
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
1115-1130	The role of PLND in the PSMA PET/CT era Associate Professor Giorgio Gandaglia	1115-1125	The influence of geography on prostate cancer outcomes Dr Natasha Roberts
1130-1145	Re-Irradiation: SBRT for retreatment of radiation failures Professor Sean Collins	1125-1135	Bridging the gap: The medical oncology nurse practitioner role in regional prostate cancer care Mr Justin Hargreaves
1145-1200	Neoadjuvant therapy in prostate cancer Professor Niall Corcoran	1135-1145	Restoring intimacy after prostate cancer: A regional erectile dysfunction workshop Ms Gaylene Corbett
1200-1210	Stereotactic ablative body radiotherapy for PSMA-PET/CT staged, oligometastatic prostate cancer – A multi-centre study Dr Gemma D'Adamo	1145-1155	Prostate cancer in the bush- keeping up with city slickers - a rural perspective in optimal patient care Mr Stu Wilder
1210-1220	Stereotactic body radiotherapy versus conventionally fractionated radiotherapy in localised prostate cancer: A systematic review of toxicity, efficacy and quality of life Dr Yonatan Adinata	1155-1205	What is the point of one day a week? Building a rural prostate cancer nursing service that makes a difference Ms Joann Oughton
1220-1230	Safety and functional outcomes of salvage radical prostatectomy following primary laser ablation for recurrent localized prostate cancer Dr Allen Guo	1205-1215	Transition from urology nurse to urology research nurse: role development and contribution to clinical trials Ms ChernXuan Lee
1230-1240	National trends in pelvic lymph node dissection during radical prostatectomy from 1997-2024 Miss Annie Le	1215-1225	The current practice of clinicians in managing prostate cancer patients on oral androgen receptor pathway inhibitors – a single specialist centre survey Mr Marc Diocera
1240-1245	Q&A discussion	1225-1235	Nurse-led innovation: embedding ePROMs in prostate cancer surveillance Ms Catherine White
		1235-1245	Q&A discussion
1245-1345	Lunch, Industry Exhibition & Poster Viewing (Melbourne Room 1)		
1345-1545	Session 5A: Clinical Urology	1345-1545	Session 5B: Nursing & Allied Health
Theme	Metastatic prostate cancer	Theme	Advancing advanced prostate cancer
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
1345-1405	Should we treat the primary in metastatic disease? A medical oncologists perspective Professor Oliver Sartor	1345-1405	Androgen receptor pathway inhibitor ARPi in metastatic castration sensitive prostate cancer Dr Shirley Wong
1405-1425	T-Cell Engagers - The final Frontier? Associate Professor Ben Tran	1405-1425	Keeping men healthy on doublet therapy Ms Debbie Victor
1425-1445	Gallium-68-PSMA-11 for prostate cancer diagnosis and Terbium-161-PSMA radioligand therapy for advanced disease Dr James Buteau	1425-1445	What's new and what's available in radioligand therapy in Australia 2026 Ms Elizabeth Medhurst
1445-1505	Safety and dosimetry of 177Lu-rosopitamab tetraxetan plus SoC in patients with metastatic castration-resistant prostate cancer: preliminary results from part 1 of phase 3 ProstACT global study Dr Aviral Singh	1445-1505	Communicating with men with prostate cancer and their families about bad news – considerations in men centred care Dr Tracey Gardiner
1505-1515	Prostate cancer characteristics in a national referral hospital in Indonesia across three decades: A retrospective study of stage and treatment Professor Agus Rizal Ardy Harlandy Hamid	1505-1525	Hope for the best, prepare for the worst Ms Debbie Victor

1515-1535	nmCRPC - yesterday, today and tomorrow Associate Professor Ben Tran	1525-1545	Q&A discussion
1535-1540	Rapid Fire Presentation Real-world outcomes and tolerability of intranasal vardenafil in men with erectile dysfunction, including a large subgroup after prostate cancer treatment Ms Melissa Hadley Barrett		
1545-1615	Afternoon Tea & Industry Exhibition (Melbourne Room 1)		
1615-1730	Multidisciplinary Plenary, Announcement of Abstract Awards & Conference Closing		
Room	<i>Melbourne Room 2</i>		
1615-1715	Management of miN1 disease in the PSMA PET/CT era - Delphi consensus <i>An APCC-led multidisciplinary expert consensus on the management of newly diagnosed PSMA node-positive but conventional imaging node-negative prostate cancer.</i>		
1715-1730	Presentation of Abstract Awards, Closing and Announcement of APCC 2027		
1900-2330	Conference Celebration		